How to Value a Plastic Surgery Practice in 2026

Plastic surgery practices are among the most valuable — and most complex — medical practices to value. The range is enormous: a small reconstructive practice dependent on insurance reimbursement might sell for 4x EBITDA, while a high-profile cosmetic surgery center with a strong brand and owned surgical suite can command 8-10x or more. I've seen the spread between the best and worst offers on the same practice exceed $3 million.

The complexity comes from the unique economics of this specialty. Nowhere else in medicine do you see the same intersection of cash-pay revenue, brand-driven patient acquisition, ancillary revenue from surgical facilities and medical spas, and the celebrity-like market dynamics where a surgeon's Instagram following can directly impact practice value.

The Multiple Range: 4-10x EBITDA

Plastic surgery practices trade at 4-10x EBITDA, one of the widest ranges in all of healthcare. The median sits around 6x EBITDAfor a well-run cosmetic-dominant practice, but where any individual practice falls depends on a few key variables that I'll break down below.

For practices where the surgeon is the sole producer and all revenue walks out the door when they do, the lower end applies. For practices that have built a brand, a team, and multiple revenue streams beyond the founding surgeon's hands, the upper end — and sometimes beyond — is realistic.

Cosmetic vs. Reconstructive: Two Different Businesses

The single most important factor in plastic surgery valuation is the revenue mix between cosmetic (elective, cash-pay) and reconstructive (insurance-based) procedures. These are economically distinct businesses operating under one roof.

Cosmetic-dominant practices (70%+ revenue from elective procedures) command premium multiples — typically 6-10x EBITDA— for three reasons. First, cash-pay revenue eliminates payer risk entirely. No insurance company is going to cut your reimbursement rates on breast augmentation. Second, cosmetic patients are elective, which means they're choosing you over competitors based on brand, reputation, and results — a competitive moat. Third, cosmetic margins are substantially higher because pricing is market-based rather than payer-dictated.

Reconstructive-dominant practices (70%+ from insurance procedures like post-mastectomy reconstruction, hand surgery, burn repair) trade at 4-6x EBITDA, more in line with other surgical specialties. The revenue is steadier but subject to payer reimbursement pressures, prior authorization requirements, and the same margin compression affecting all insurance-based medicine.

A mixed practice — 50/50 cosmetic and reconstructive — often gets valued as two separate streams, weighted by their respective multiples. This blended approach is fairer than applying a single multiple to the whole practice.

The Cash-Pay Premium

In medical practice valuation, cash-pay revenue is gold. Plastic surgery is one of the few specialties where cash-pay can represent 60-90% of total revenue, and this fundamentally changes the valuation equation.

Cash-pay revenue means no accounts receivable aging, no insurance claim denials, no prior authorizations, and no reimbursement rate cuts. Collection rates on cosmetic procedures are effectively 100% because payment is collected at or before the time of service. Compare that to an insurance-based practice where net collection rates might be 85-92% after denials, write-offs, and bad debt.

Buyers price this efficiency directly. A practice collecting $3M with $2.5M from cash-pay cosmetic and $500K from insurance-based reconstructive is worth meaningfully more than a practice collecting $3M entirely from insurance — even if EBITDA is identical today — because the cash-pay revenue is more durable, more predictable, and more scalable.

Surgical Center Ownership: The Multiplier

The single biggest value driver I see in plastic surgery — beyond the surgeon themselves — is ownership of an ambulatory surgery center (ASC) or in-office operating suite. When the practice owns and operates its surgical facility, it captures two revenue streams: the professional fee for the surgeon's work and the facility fee for the operating room, anesthesia, and supplies.

Facility fees on cosmetic surgery cases can represent 30-50% of the total case revenue. A breast augmentation that generates $8,000 in surgeon fees might generate another $3,000-$5,000 in facility fees. A practice that owns its surgical suite captures all of this; one that operates out of a hospital or third-party ASC captures none of it.

The valuation impact is substantial. Practices with owned surgical facilities typically have EBITDA margins of 30-45%, versus 20-30%for practices without. And the multiple itself is higher because the facility provides a competitive moat — it's expensive to build, requires state licensing and accreditation, and represents a barrier that competitors can't easily replicate.

Brand, Reputation, and Marketing Spend

Plastic surgery is one of the most marketing-intensive medical specialties. Practices routinely spend 8-15% of revenue on marketing, compared to 2-5% for most other medical practices. This creates an interesting valuation dynamic: high marketing spend suppresses current EBITDA but may be building long-term brand value.

Buyers evaluate marketing economics through three lenses. Patient acquisition cost — what does it cost to get a new cosmetic consultation? Well-run practices achieve this for $150-$400 per consultation; poorly run ones spend $800+. Consultation-to-surgery conversion rate — top practices convert 50-70% of consultations into booked procedures; the industry average is closer to 35-45%. Revenue per marketing dollar — a practice spending $300K on marketing to generate $3M in revenue (10:1 return) is more valuable than one spending $300K to generate $1.5M (5:1).

The surgeon's personal brand is a double-edged sword. A strong social media presence, media appearances, and name recognition drive patient volume — but they also create extreme owner dependency. Buyers will discount the value of a practice where 80% of patients come specifically for "Dr. Celebrity" because that revenue evaporates when the surgeon leaves.

What Kills Value in Plastic Surgery

Single-surgeon dependency. This is the number one value destroyer. If the founding surgeon performs 90% of procedures and patients book specifically for them, the buyer is purchasing a practice that will likely lose 30-50% of revenue upon transition. Practices with two or more surgeons — even if one is clearly the "star" — sell for meaningfully higher multiples.

Malpractice history. Cosmetic surgery carries elevated malpractice risk compared to other specialties, and any history of claims, settlements, or adverse outcomes requires careful evaluation. A single large settlement won't necessarily kill a deal, but a pattern of claims signals systemic quality issues that will dramatically reduce the buyer pool.

Declining procedure volume. Cosmetic surgery is discretionary and sensitive to economic conditions. If your practice shows declining case volume over 2-3 years — even if revenue is stable because you've raised prices — buyers will notice. Volume trends are a leading indicator that matters more than revenue trends in this specialty.

Non-transferable brand. If the practice is named after the surgeon (Dr. Smith Plastic Surgery), the website features only the founding surgeon, and marketing is built entirely around their personal brand, the value that transfers to a buyer is limited. Practices with brand identities independent of the surgeon — a center name, multi-provider marketing, and institutional branding — transfer more cleanly.

Maximizing Value Before Sale

Add a second surgeon. Even if they handle 20-30% of cases, proving the practice can generate revenue without the founding surgeon is the single highest-impact move. The cost of a second surgeon is recouped many times over in the valuation premium.

Build non-surgical revenue. Medical spa services — injectables, laser treatments, skin care — generate high-margin revenue that's less surgeon-dependent. A practice where non-surgical aesthetics represent 20-30% of revenue is more attractive than one that's 100% surgical.

Invest in the surgical facility. If you don't own an ASC or in-office OR, this is worth exploring 2-3 years before sale. The capital investment is significant ($500K-$2M depending on scope), but the EBITDA impact and multiple expansion can more than justify it.

Transition your brand. Start shifting marketing from your personal name to the practice name. Feature associate surgeons and nurse practitioners in marketing materials. Build a brand identity that exists independent of you. This takes time, which is why starting 2-3 years before sale matters.

The Bottom Line

Plastic surgery practice valuation sits at the intersection of healthcare economics and brand economics. The cash-pay model, surgical facility ownership, and marketing-driven patient acquisition create a valuation landscape unlike any other medical specialty. The practices that command top multiples are the ones that have built value beyond a single surgeon's reputation — through a team, a brand, a facility, and multiple revenue streams. The ones that sell at the bottom are the ones where the surgeon is the brand, the brand is the surgeon, and everything leaves when they do.